Athenex’s R & D operations are focused on cancer but its Pharmaceutical Division, which has a focus on sterile injectables, has a broader base. Commercial product sales for FY2022 are likely to be ~US$110m.
Athenex markets 30 or so sterile injectable products, sourced through licence and development agreements, of which approximately a third are for cancer. But their commercial sterile injectable portfolio also includes 5 antibiotics (daptomycin isn’t one of them), 2 drugs for sedation (propofol isn’t one of them) and melphalan, which Avecho has reformulated as part of its TPM-enhanced sterile injectable portfolio.
On its website, Athenex states
We are always looking for innovative, unique presentations that enhance safety or reduce the number of steps required to administer.
That pretty much describes the raison d’etre for AVE’s TPM-enhanced sterile injectables.
https://www.athenexpharma.com/products/
About - Athenex Pharmaceuticals
Ann: Athenex submits Avecho's phytonadione to FDA pre-IND, page-8
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.508M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $6.592K | 2.204M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 96714175 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 19678077 | 12 |
View Market Depth
| Last trade - 15.57pm 21/06/2024 (20 minute delay) ? |
| AVE (ASX) Chart |